Changes in Brain Natriuretic Peptide Levels and Bioelectrical Impedance Measurements After Treatment With High-Dose Furosemide and Hypertonic Saline Solution Versus High-Dose Furosemide Alone in Refractory Congestive Heart Failure

Paterna, Salvatore; Pasquale, Pietro Di; Parrinello, Giovanni; Fornaciari, Ersilia; Gaudio, Francesca Di; Fasullo, Sergio; Giammanco, Marco; Sarullo, Filippo M.; Licata, Giuseppe

doi:10.1016/j.jacc.2005.01.059

Cited by 167 publications

(79 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both segmental and whole body BIA had a significant correlation with BNP values [37] and patients undergoing diuretic therapy for heart failure had a significant increase in resistance and reactance post therapy [38,39]. Finally, a study by Paterna et al, found that BIA could be used to monitor resolution of fluid overload in heart failure patients [39].…”

Section: Bioimpedancementioning

confidence: 99%

Fluid-Volume Assessment in the Investigation of Acute Heart Failure

Tuy

Than

2013

Curr Emerg Hosp Med Rep

View full text Add to dashboard Cite

Heart failure is a syndrome whereby cardiac function is incapable of providing for the body's circulatory demands, resulting in hemodynamic and volumetric aberrations. Acute heart failure (AHF) is the condition where signs and symptoms of heart failure are present that require urgent intervention. In AHF impaired cardiac function progresses to hemodynamic congestion and eventually develops into a fluid overloaded state. These patients will typically present acutely for medical assistance, with signs and symptoms of fluid overload (dyspnea, paroxysmal nocturnal dyspnea, orthopnea, edema, etc.) and/or hypoperfusion (malaise, altered mental status, decreased urine output). In patients with AHF, volume assessment is a crucial step in the initial diagnosis.

show abstract

Section: Bioimpedancementioning

confidence: 99%

Fluid-Volume Assessment in the Investigation of Acute Heart Failure

Tuy

Than

2013

Curr Emerg Hosp Med Rep

View full text Add to dashboard Cite

show abstract

“…The addition of hypertonic saline solution to furosemide has yielded beneficial hemodynamic and diuretic effects that persist long term [39]. However, this therapeutic approach cannot be recommended for clinical practice until further prospective trials have evaluated it.…”

Section: Acute Crs (Type 1)mentioning

confidence: 99%

Pharmacologic Therapies for Chronic and Acute Decompensated Heart Failure: Specific Insights on Cardiorenal Syndromes

et al. 2014

View full text Add to dashboard Cite

In the setting of cardiorenal syndrome(s) (CRS), the main pathophysiological triggers of renal disease progression include increases in renal venous pressure, maladaptive activation of the renin-angiotensin-aldosterone (RAAS) and the sympathetic nervous systems, and a chronic inflammatory state. In acute decompensated heart failure (HF)/type 1 CRS, diuretics remain the mainstay of first-line therapy in order to prevent congestion and renal venous hypertension. In chronic HF/type 2 CRS, RAAS multiple inhibition has been recommended in addition to diuretics. However, cotreatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and mineralocorticoid receptor antagonists is likely to lead to more frequent occurrences of hyperkalemia and worsening renal function. In this review, the main pharmacological therapies of acute and chronic CRS are discussed regarding their indication as well as intended and side effects. Future therapies are suggested, underlining that a multidisciplinary approach to a deeper understanding of the pathophysiology of CRS is still required to improve specific treatment and clinical outcome.

show abstract

“…Also, Appel fails to cite 3 relevant heart failure trials, all consistently show harm with reduced sodium intake. [7][8][9] Conclusions of Appel are based on-if not biased by-a single surrogate end point (BP) for which the evidence for sodium restriction is not compelling. Effects on other surrogate outcomes should give pause, and the only existing data on important patient-oriented outcomes should make a decided case for hesitation, not action, when it comes to reducing population sodium intake.…”

Section: To the Editormentioning

confidence: 99%

Letter by DiNicolantonio et al Regarding Article, “Reducing Sodium Intake to Prevent Stroke: Time for Action, Not Hesitation”

DiNicolantonio

Lucan

O’Keefe

2014

Stroke

View full text Add to dashboard Cite

Changes in Brain Natriuretic Peptide Levels and Bioelectrical Impedance Measurements After Treatment With High-Dose Furosemide and Hypertonic Saline Solution Versus High-Dose Furosemide Alone in Refractory Congestive Heart Failure

Abstract: Our data show that the HSS group reached dry weight more rapidly, a significantly faster reduction in BNP levels, shorter hospitalization stay, and lower incidence in readmissions in the 30-day study period.

Cited by 167 publications

References 36 publications

Fluid-Volume Assessment in the Investigation of Acute Heart Failure

Fluid-Volume Assessment in the Investigation of Acute Heart Failure

Pharmacologic Therapies for Chronic and Acute Decompensated Heart Failure: Specific Insights on Cardiorenal Syndromes

Letter by DiNicolantonio et al Regarding Article, “Reducing Sodium Intake to Prevent Stroke: Time for Action, Not Hesitation”

Contact Info

Product

Resources

About